Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
The facility is expected to be completed in 2024
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
These media reports are based on incorrect facts and are without any basis.
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated